Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around
Principal Investigator
by Judith S. Currier, MD (ucla)
Headshot of Judith S. Currier
Judith S. Currier

Description

Summary

This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.

Details

Keywords

Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis, Inflammation, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, Bempedoic acid, Bempedoic acid (BA)

Eligibility

Location

  • San Francisco General Hospital accepting new patients
    San Francisco California 94110 United States

Lead Scientist at University of California Health

  • Judith S. Currier, MD (ucla)
    Dr. Judith S. Currier serves as the Executive Vice Chair for Research in the Department of Medicine and as Co-Director of the Center for Clinical AIDS Research and Education. She holds the Michael and Sue Steinberg Endowed Chair in Global AIDS Prevention and Policy Research.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Priscilla Hsue, MD
ID
NCT05488431
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 121 study participants
Last Updated